New pivotal trial milestones in multiple sclerosis and head and neck cancer, plus key collaboration and funding moves, …
New pivotal trial milestones in multiple sclerosis and head and neck cancer, plus key collaboration and funding moves, …
Several Phase 1 and Phase 2 trials report encouraging results this month, amplifying momentum in precision psychiatry, respiratory …
Researchers propose a new framework that combines domestic real-world data with overseas trial data to make global clinical …
New research unveiled at the American Association for Cancer Research meeting points to promising treatments for head and …
New trial presents and preclinical readouts set to shape the oncology landscape
Zydus’ experimental therapy demonstrates significant improvements in liver function and patient outcomes, signaling new hope in a disease …
Fresh guidelines and a reshaped regulatory framework pave the way for smoother clinical research, even as COVID-19 maintains …
The sudden departure of FDA’s Peter Marks raises uncertainty across the biopharma sector amid ongoing regulatory scrutiny and …
Alnylam’s Fitusiran gains FDA approval as a first RNAi therapeutic for hemophilia, while Vertex discontinues its innovative insulin-producing …
The FDA approval of Alnylam’s Fitusiran marks a milestone in RNA interference therapeutics, while Vertex discontinues a novel …
Already a subscriber? Log in